Strategic partnerships OBD has a track record of 40+ partnerships with pharma and leading medical institutions, including Pfizer, Genentech, Roche, Biogen, and Mayo Clinic, indicating strong collaboration channels and potential co-development or distribution opportunities for EpiSwitch tests and related tools.

Clinical expansion Recent product launches and regional collaborations, such as the US launch of EpiSwitch Prostate Screening and partnerships with clinics like The London Clinic and Goodbody Clinic, suggest growing demand pathways and potential access points for new tests and expanded geographies.

Cloud analytics Google Cloud collaboration and a cloud-based analytical framework for precision medicine point to scalable data processing capabilities; this creates opportunities to upsell advanced analytics services, customized reporting, and integration with customers’ health IT ecosystems.

Revenue growth signals Interim revenue increases and reported six-month revenue growth reflect improving commercial traction; this momentum could support efforts to expand inside sales, deepen adoption of CiRT and PSE tests, and pursue larger multi-site payer or lab network deals.

Global lab footprint Multiple ISO-certified and CLIA-partnered labs across the UK, USA, and Malaysia create a robust global launch and service delivery network, enabling faster test turnaround, broader payer access, and potential regional trends to target with co-marketing and localizable solutions.